Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer
Irene Peris, Terrance James Haanen, Alexander Day, Jiang Hu, Catherine G. Callahan, Gabrielle Hodges Onishi, Kaitlin P. Zawacki, Brian Tran, Alexis Harold, Amanda C. Dowdican, Charles A. Nino, Wei Huang, Daniel Léonard, Matthew Hinderman, Kelsey Barrie, Brynne Raines, Jaya Sangodkar, Sophie Boock, Varsha Shankar, Miranda Giambi, Silvia Romero-Murillo, Leah Arbitman, Shirish Shenolikar, George L. Trainor, Frédéric Cachoux, Obdulia Rabal, Olga Gherbovet, Laura Fourmois, David L. Brautigan, Analisa DiFeo, Derek J. Taylor, Caitlin M. O’Connor, Goutham Narla
Peer-reviewed journalBold claims, read criticallyClaims a big stepReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.
We conducted a large meta-analysis of melanoma GWAS, including 35 GWAS from 29 cohorts (69,871 cases; 1,616,233 controls) identifying 156 independent signals at 116 risk loci.
G. J. M. S. R. Jayasinghe, J. Shi, R. Thakur and 42 more — medRxiv
Conclusions: In older women, early breast cancer and its treatment did not lead to accelerated decline in functional status or cognitive function within the first year compared to matched older women without cancer.
W. G. van der Plas-Krijgsman, J. W. Blom, M. G. M. Derks and 12 more — medRxiv
Conclusion: Host inflammatory and albumin changes added information about adjuvant initiation beyond tumour pathology, and initiation was associated with longer survival.
B. Jiao, S. Alotaibi, K. Abumelha and 12 more — medRxiv